<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>25A. Transplantation Immunology</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="immunology-24d-type4-hypersensitivity.html" class="nav-button"> 
                        <span class="nav-icon"></span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 94.87%;"></div> <!-- (37/39)*100 -->
                        </div>
                       <span class="progress-text">Lecture 37 of 39</span> 
                    </div>
                    <a href="immunology-25b-transplantation-immunology-details.html" class="nav-button"> 
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon"></span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">Transplantation Immunology</h1>
                <p>Dr. Barasa AK</p>
                <p>200818</p>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                <!-- START: section-learning-objectives -->
                <section id="section-learning-objectives" class="content-section" aria-labelledby="section-heading-learning-objectives">
                    <h2 id="section-heading-learning-objectives" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Learning Objectives</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Understand the basics of transplantation</li>
                            <li>Describe the mechanisms of T cell recognition of antigen</li>
                            <li>Understand the effector pathways of graft injury</li>
                            <li>Describe the aetiology and pathophysiology of GVHD</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-learning-objectives -->

                <!-- START: section-introduction -->
                <section id="section-introduction" class="content-section" aria-labelledby="section-heading-introduction">
                    <h2 id="section-heading-introduction" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Introduction</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Transfer of cells, tissues or organs (graft) from one part of the body to another, or from one individual to another</li>
                            <li>Used to replace organs or tissues that have failed e.g. in
                                <ul>
                                    <li>ESRD</li>
                                    <li>Heart failure</li>
                                    <li>Cirrhosis</li>
                                    <li>Leukaemia</li>
                                </ul>
                            </li>
                            <li>Can use cadaveric or living donors</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-introduction -->

                <!-- START: section-genetic-barriers -->
                <section id="section-genetic-barriers" class="content-section" aria-labelledby="section-heading-genetic-barriers">
                    <h2 id="section-heading-genetic-barriers" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Genetic Barriers to Transplantation</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>The main immunological problem with transplantation is rejection</li>
                            <li>Grafted organ or tissue is seen as 'foreign' by the immune system</li>
                            <li>It is then recognized and attacked</li>
                            <li>The genetic relationship between the donor & recipient determines whether or not rejection will occur</li>
                            <li>Autografts and isografts usually accepted</li>
                            <li>Allografts and xenografts usually rejected</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_06_15_b759ac58ebcb239352ffg-05-1.jpg" alt="Diagram illustrating types of grafts: Autograft (self to self, accepted), Isograft (identical twin to twin, accepted), Allograft (different individual, same species, rejected), Xenograft (different species, rejected)." class="content-image">
                            <figcaption>Immunology by David Male et al, 8<sup>th</sup></figcaption>
                        </figure>
                    </div>
                </section>
                <!-- END: section-genetic-barriers -->

                <!-- START: section-organ-donation -->
                <section id="section-organ-donation" class="content-section" aria-labelledby="section-heading-organ-donation">
                    <h2 id="section-heading-organ-donation" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Organ Donation</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Shortage of donors is a limiting factor for organ transplantation</li>
                            <li>One cadaveric donor can provide many organs for transplantation</li>
                            <li>Potential solutions to increase the number of donors include :
                                <ul>
                                    <li>Advertising and donor recruitment campaigns</li>
                                    <li>Role of legislation*</li>
                                    <li>'Presumed consent' - policy whereby everyone is assumed to have given consent for their organs to be used, unless they indicate otherwise</li>
                                    <li>'Opt in' approach - individuals/relatives have to give permission for organs to be used</li>
                                    <li>Increasing facilities for organ harvesting, including transplant coordinators, surgical teams</li>
                                    <li>Relaxing donor selection criteria - allow use of organs that would not have been used previously
                                        <ul>
                                            <li>E.g. use of non heart beating donors</li>
                                            <li>Marginal donors (older donors, those with diseases that would have previously excluded them)</li>
                                        </ul>
                                    </li>
                                    <li>Use of living donors or animal donors</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-organ-donation -->

                <!-- START: section-ethical-issues-living-donation -->
                <section id="section-ethical-issues-living-donation" class="content-section" aria-labelledby="section-heading-ethical-issues-living-donation">
                    <h2 id="section-heading-ethical-issues-living-donation" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Ethical Issues in Living Donation</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Used in situations where the donation of an organ poses little risk to the living donor
                                <ul><li>E.g. kidney transplantation - it is possible to live with just one healthy kidney</li></ul>
                            </li>
                            <li>It is also possible to donate a lobe of a liver, as it can regrow</li>
                            <li>Donation of a lung lobe is also possible, but much riskier</li>
                            <li>Haematopoietic stem cell transplants also involve living donors</li>
                            <li>Potential donor should be healthy</li>
                            <li>Donation should be compatible (appropriate blood group)</li>
                            <li>Donor should be aware of the risks & should not be coerced into giving an organ</li>
                            <li>Majority of donations carried out between close relatives and friends</li>
                            <li>Some cases - altruistic donors</li>
                            <li>In most countries it is illegal to sell organs for transplantation</li>
                            <li>Organ exchange programs to maximize the number of transplants formed - paired donations</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-ethical-issues-living-donation -->

                <!-- START: section-graft-rejection -->
                <section id="section-graft-rejection" class="content-section" aria-labelledby="section-heading-graft-rejection">
                    <h2 id="section-heading-graft-rejection" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Graft Rejection</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Immune response in which the recipient immune system responds to & attacks the donor tissue due to immune recognition of antigenic differences between the donor organ & the recipient</li>
                            <li>MHC molecules are the major target for rejection</li>
                            <li>Ability to accept a graft is dependent on the recipients sharing all the donor's histocompatibility genes</li>
                            <li>Animal that differ at loci other than MHC reject graft from each other, but more slowly</li>
                            <li>Adaptive immune response - shows memory</li>
                            <li>Once an animal has rejected an organ graft the first time, if a second graft is performed from the same species or donor, it is rejected more rapidly (second set rejection)</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_06_15_b759ac58ebcb239352ffg-12-1.jpg" alt="Graph illustrating first-set and second-set graft rejection. First-set rejection occurs after several days. Second-set rejection of a graft from the same donor is much faster, demonstrating immunological memory." class="content-image">
                        </figure>
                        <ul>
                            <li>In a primary alloresponse, most of the alloreactive CD4 or CD8 T cells directly recognise the donor MHC molecules displayed by donor APCs in the graft (direct response/presentation/pathway)</li>
                            <li>However, there are other forms of alloresponse:
                                <ul><li>Against minor MHC antigens</li></ul>
                            </li>
                            <li>Indirect response - recipient CD4 T cells recognise donor MHC molecules that have been processed by recipient APCs, presented in context of recipients MHC II molecules
                                <ul><li>(similar to conventional T cell recognition of antigens e.g. pathogens). CD8 cells only see alloantigen by the direct pathway</li></ul>
                            </li>
                            <li>The indirect pathway of recognition occurs in lower frequency but is important during chronic rejection (very few donor-derived professional APCs to stimulate a direct immune response)</li>
                        </ul>
                        <figure>
                             <img src="../assets/images/2025_06_15_b759ac58ebcb239352ffg-15-1.jpg" alt="Diagram comparing direct and indirect allorecognition. Direct: Recipient T cell recognizes intact donor MHC on donor APC. Indirect: Recipient APC processes donor MHC and presents donor peptides on self MHC to recipient T cell." class="content-image">
                            <figcaption>1. direct allorecognition<br>2. indirect allorecognition<br>Immunology by David Male et al,</figcaption>
                        </figure>
                        <ul>
                            <li>Minor histocompatibility antigens can be the targets of rejection even when the MHC is identical between donor and recipient</li>
                            <li>Their nature assumed to be normal polymorphic molecules, peptides from which bind to host MHC and induce an immune response</li>
                            <li>Can be tissue-specific</li>
                            <li>E.g. H-Y system - antigens encoded by the Y chromosome; expressed only on male cells</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_06_15_b759ac58ebcb239352ffg-17-1.jpg" alt="Diagram illustrating rejection due to H-Y minor histocompatibility antigens. A female mouse (XX) rejects a skin graft from a syngeneic male mouse (XY) due to Y-chromosome encoded antigens presented on MHC class I." class="content-image">
                            <figcaption>H-Y minor histocompatibility antigens<br>Immunology by David Male et al,</figcaption>
                        </figure>
                    </div>
                </section>
                <!-- END: section-graft-rejection -->

                <!-- START: section-immune-effector-mechanisms -->
                <section id="section-immune-effector-mechanisms" class="content-section" aria-labelledby="section-heading-immune-effector-mechanisms">
                    <h2 id="section-heading-immune-effector-mechanisms" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Immune Effector Mechanisms in Graft Rejection</span>
                    </h2>
                    <div class="content-card">
                        <p>Rejection can occur at various times, each associated with different immune effector mechanisms</p>
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Types of Graft Rejection</caption>
                                <thead>
                                    <tr>
                                        <th>type of rejection</th>
                                        <th>time taken</th>
                                        <th>mechanisms of rejection</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>hyperacute rejection</td>
                                        <td>minutes to hours</td>
                                        <td>preformed anti-donor antibodies</td>
                                    </tr>
                                    <tr>
                                        <td>acute rejection</td>
                                        <td>days to weeks</td>
                                        <td>activation of alloreactive T cells</td>
                                    </tr>
                                    <tr>
                                        <td>chronic rejection</td>
                                        <td>months to years</td>
                                        <td>slow cellular response, response of organ to injury, unknown causes</td>
                                    </tr>
                                </tbody>
                            </table>
                            <p class="caption-text" style="text-align: right; font-size: 0.9em; color: var(--muted-text-color);">Immunology by David Male et al, 8<sup>th</sup></p>
                        </div>
                    </div>
                </section>
                <!-- END: section-immune-effector-mechanisms -->

                <!-- START: section-hyperacute-rejection -->
                <section id="section-hyperacute-rejection" class="content-section" aria-labelledby="section-heading-hyperacute-rejection">
                    <h2 id="section-heading-hyperacute-rejection" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Hyperacute Rejection</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Immediate</li>
                            <li>Mediated by pre-existing antibody</li>
                            <li>Individual sensitized to donor MHC e.g. previous transplants, multiple blood transfusions or pregnancy</li>
                            <li>Natural pre-existing antibodies e.g. ABO blood group incompatibility</li>
                            <li>Rejection seen within minutes of connecting the circulation into the transplanted organ</li>
                            <li>Pre-existing antibodies bind to the endothelial cells lining the blood vessels and initiate immune effector functions</li>
                            <li>Complement activation by the classical pathway</li>
                            <li>Complement activation leads to death of the endothelium, or, when damage is sub-lethal, activation of the endothelial cells</li>
                            <li>Causes an inflammatory response increasing vascular leakage and coagulation</li>
                            <li>Results in rapid destruction of the graft</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_06_15_b759ac58ebcb239352ffg-21-1.jpg" alt="Diagram illustrating hyperacute rejection. Pre-existing antibodies in the recipient bind to donor endothelial cells, activate complement, leading to endothelial damage, inflammation, thrombosis, and rapid graft destruction." class="content-image">
                        </figure>
                        <p><strong>Prevention:</strong></p>
                        <ul>
                            <li>ABO matching</li>
                            <li>Cross-matching donor and recipient
                                <ul><li>Donor leucocytes incubated with recipient serum in the presence of serum complement</li></ul>
                            </li>
                            <li>Cell death indicates presence of anti-donor antibody. Is a contraindication to proceeding with transplantation</li>
                            <li>Performed immediately before the surgery</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-hyperacute-rejection -->

                <!-- START: section-acute-rejection -->
                <section id="section-acute-rejection" class="content-section" aria-labelledby="section-heading-acute-rejection">
                    <h2 id="section-heading-acute-rejection" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Acute Rejection</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Seen in days to weeks after transplantation</li>
                            <li>Caused by activation of allospecific T cells capable of damaging the graft</li>
                            <li>Following transplantation, donor dendritic cells present in the organ (passenger leucocytes) migrate to the lymph nodes draining the organ and stimulate a primary alloimmune response</li>
                            <li>Activated T cells migrate to the organ and cause tissue damage by
                                <ul>
                                    <li>Generation of T<sub>C</sub> cells</li>
                                    <li>Induction of DTH reactions</li>
                                </ul>
                            </li>
                            <li>If the patient has already been exposed to the alloantigens expressed by the graft, there will be alloreactive memory cells, leading to accelerated rejection of the graft</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-acute-rejection -->

                <!-- START: section-chronic-rejection -->
                <section id="section-chronic-rejection" class="content-section" aria-labelledby="section-heading-chronic-rejection">
                    <h2 id="section-heading-chronic-rejection" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Chronic Rejection</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Seen months to years after transplantation</li>
                            <li>In vascularized organs, presents as occlusion of blood vessels - narrowed lumen due to thickening of the intima by smooth muscle proliferation and mononuclear cell infiltrate</li>
                            <li>Eventually leads to blockage of the blood vessels and subsequent ischaemia of the organ</li>
                            <li>The parenchyma is slowly replaced by nonfunctioning fibrous tissue</li>
                        </ul>
                        <h3 class="subsection-heading">Mechanisms of Chronic Rejection</h3>
                        <ul>
                            <li>Low-grade T cell response (indirect allospecific pathway due to loss of passenger leucocytes that activate T cells with direct pathway specificity)</li>
                            <li>Antibody (indicated by deposition of complement component C4d - in tissues)</li>
                            <li>Non immunological processes:
                                <ul>
                                    <li>Response of the graft to injury caused at the time of transplantation or by acute rejection episodes</li>
                                    <li>Recurrence of the original underlying disease</li>
                                    <li>Drug-related toxicities</li>
                                </ul>
                            </li>
                            <li>Chronic rejection responds poorly to current immunosuppressive therapy</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-chronic-rejection -->

                <!-- START: section-gvhd -->
                <section id="section-gvhd" class="content-section" aria-labelledby="section-heading-gvhd">
                    <h2 id="section-heading-gvhd" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Graft versus Host Disease</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Occurs when competent immune cells (donor T cells) are transplanted into a recipient e.g. in BMT when normal donor T cells may be infused into the recipient</li>
                            <li>The T cells can recognise the MHC molecules &/or minor histocompatibility antigens of the recipient as foreign, and produce an immune response against the recipient</li>
                            <li>Occurs when the recipient is immunocompromised
                                <ul>
                                    <li>BMT</li>
                                    <li>Neonatal blood transfusion</li>
                                </ul>
                            </li>
                            <li>Can be lethal</li>
                            <li><strong>Acute GvHD</strong> - epithelial cell death in the skin, liver and GIT
                                <ul><li>Rash, jaundice, diarrhoea, GI haemorrhage</li></ul>
                            </li>
                            <li><strong>Chronic GvHD</strong> - fibrosis and atrophy of one or more organs without evidence of acute cell death
                                <ul><li>Complete dysfunction of affected organ</li></ul>
                            </li>
                        </ul>
                        <h3 class="subsection-heading">GvHD - Prevention and Treatment</h3>
                        <ul>
                            <li>Elimination of mature T cells from the graft and APCs from the host</li>
                            <li>BMT
                                <ul>
                                    <li>Treat bone marrow to deplete T cells</li>
                                    <li>Use autologous bone marrow</li>
                                    <li>Use umbilical cord blood</li>
                                </ul>
                            </li>
                            <li>GvHD is treated by immunosuppression</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-gvhd -->

                <!-- START: section-hla-matching -->
                <section id="section-hla-matching" class="content-section" aria-labelledby="section-heading-hla-matching">
                    <h2 id="section-heading-hla-matching" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">HLA Matching</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>The major antigenic differences recognized by the alloimmune response are found on MHC molecules (HLA)</li>
                            <li>Matching the donor & recipient to minimize antigenic differences (so that they share as many alleles as possible)</li>
                            <li>The better the HLA matching of donor & recipient, the less the strength of rejection</li>
                            <li>Performed using PCR</li>
                            <li>Matching is rarely perfect between unrelated donors because of the difficulty in matching all MHC I & II gene loci & the high level of polymorphism at each locus</li>
                            <li>Potentially 12 different loci of maternal & paternal HLA class I (HLA-A, -B, -C) & class II loci (HLA-DR, -DP, DQ)</li>
                            <li>Hundreds of variants of each antigen</li>
                            <li>Very important in BMT</li>
                            <li>Also has a significant influence on the outcome of kidney transplantation</li>
                            <li>No benefit in corneal transplantation</li>
                            <li>For those organs where transplantation is essential to maintain life (heart & liver), there is no possibility of waiting for a well-matched organ to become available</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-hla-matching -->

                <!-- START: section-immunosuppressive-drugs -->
                <section id="section-immunosuppressive-drugs" class="content-section" aria-labelledby="section-heading-immunosuppressive-drugs">
                    <h2 id="section-heading-immunosuppressive-drugs" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Immunosuppressive Drugs</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Control the alloimmune response</li>
                            <li>Rejection episodes still occur but are kept in check, to minimize lasting damage</li>
                            <li>Cause blanket suppression of the immune system</li>
                            <li>Recipients more prone to opportunistic infections & have a higher incidence of malignancies</li>
                            <li>Strategies to promote specific immunological tolerance a subject of interest</li>
                            <li>Present challenge is to use the currently available agents well to minimize side effects while preserving graft function</li>
                        </ul>
                        <h3 class="subsection-heading">Antiproliferative drugs</h3>
                        <ul>
                            <li>Inhibit synthesis of purines required for cell division
                                <ul>
                                    <li>6-MP</li>
                                    <li>Azathioprine - purine antagonist that competes with inosine monophosphate</li>
                                    <li>Mycophenolic acid - inhibits inosine monophosphate dehydrogenase which is essential in the de-novo synthesis of purines</li>
                                </ul>
                            </li>
                        </ul>
                        <h3 class="subsection-heading">Inhibitors of T cell activation</h3>
                        <ul>
                            <li><strong>Ciclosporin</strong> - binds to cyclophilin, inhibiting calcineurin (a calcium-dependent phosphatase) which would otherwise activate the NFAT complex & lead to IL-2 gene transcription; thereby inhibiting IL-2 production</li>
                            <li><strong>Tacrolimus</strong> - binds to FK-binding protein 12, an intracellular protein; the resulting complex inhibits calcineurin</li>
                            <li><strong>Sirolimus/Rapamycin</strong> - inhibits signals transmitted by IL-2 binding to IL-2R (sirolimus)</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_06_15_b759ac58ebcb239352ffg-36-1.jpg" alt="Diagram illustrating the mechanisms of action of T cell activation inhibitors: Ciclosporin and Tacrolimus inhibiting calcineurin and NFAT activation (blocking IL-2 production), and Sirolimus (Rapamycin) inhibiting mTOR pathway downstream of IL-2 receptor signaling (blocking proliferation)." class="content-image">
                        </figure>
                        <h3 class="subsection-heading">Anti-inflammatories</h3>
                        <ul>
                            <li><strong>Corticosteroids</strong>
                                <ul>
                                    <li>Inhibit proinflammatory cytokine secretion - IL-1, -3, 4, -5, -8, TNF$\alpha$</li>
                                    <li>Inhibit nitric oxide synthase</li>
                                    <li>Inhibit expression of adhesion molecules, leading to reduced inflammatory cell migration</li>
                                    <li>Induction of endonucleases leading to apoptosis in lymphocytes & eosinophils</li>
                                </ul>
                            </li>
                        </ul>
                        <h3 class="subsection-heading">Antibody therapy</h3>
                        <ul>
                            <li><strong>Anti-lymphocyte globulin/anti-thymocyte globulin</strong>
                                <ul><li>Polyclonal antibodies raised by immunizing rabbits or horses with lymphocytes or thymocytes</li><li>Deplete circulating T cells</li></ul>
                            </li>
                            <li><strong>Monoclonal antibodies</strong>
                                <ul>
                                    <li>Muromonab-CD3 - binds to CD3 on T cells, suppressing T cell responses</li>
                                    <li>Daclizumab & Basiliximab - anti-IL-2 receptors</li>
                                    <li>Alemtuzumab (CAMPATH-1 H) - depletes CD52 expressing leucocytes</li>
                                    <li>Rituximab - anti-CD20; depletes B cells</li>
                                    <li>Abatacept & Belatacept - fusion proteins of CTLA4 with Fc portion of antibody</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-immunosuppressive-drugs -->

                <!-- START: section-donor-specific-tolerance -->
                <section id="section-donor-specific-tolerance" class="content-section" aria-labelledby="section-heading-donor-specific-tolerance">
                    <h2 id="section-heading-donor-specific-tolerance" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Induction of Donor-Specific Tolerance</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Immune system specifically becomes nonresponsive to the donor antigens, but is capable of responding normally to other antigens</li>
                            <li>Demonstrated in animal models but difficult to translate into the clinical setting</li>
                            <li>Alloreactive T cells can be anergized by blockade of co-stimulatory signals such as CD80 & CD86 with CTLA-4-Ig, as a way of inducing tolerance</li>
                            <li>Alternative is to induce a regulatory response to the alloantigen</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_06_15_b759ac58ebcb239352ffg-41-1.jpg" alt="Diagram illustrating co-stimulation blockade for tolerance induction. A T cell requires TCR signal (Signal 1) and co-stimulatory signal (CD28-B7, Signal 2) for activation. CTLA4-Ig binds to B7, blocking Signal 2 and leading to T cell anergy or tolerance." class="content-image">
                            <figcaption>Co-stimulation blockade<br>Immunology by David Male et al, 8<sup>th</sup></figcaption>
                        </figure>
                    </div>
                </section>
                <!-- END: section-donor-specific-tolerance -->

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="immunology-24d-type4-hypersensitivity.html" class="nav-button"> 
                        <span class="nav-icon"></span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 94.87%;"></div> 
                        </div>
                       <span class="progress-text">Lecture 37 of 39</span> 
                    </div>
                    <a href="immunology-25b-transplantation-immunology-details.html" class="nav-button"> 
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon"></span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script> 
</body>
</html>